CA2477714A1 - New cinnamic acid salts, processes for the preparation thereof and use thereof as medicament - Google Patents
New cinnamic acid salts, processes for the preparation thereof and use thereof as medicament Download PDFInfo
- Publication number
- CA2477714A1 CA2477714A1 CA002477714A CA2477714A CA2477714A1 CA 2477714 A1 CA2477714 A1 CA 2477714A1 CA 002477714 A CA002477714 A CA 002477714A CA 2477714 A CA2477714 A CA 2477714A CA 2477714 A1 CA2477714 A1 CA 2477714A1
- Authority
- CA
- Canada
- Prior art keywords
- enantiomers
- racemates
- mixtures
- compounds
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention relates to novel cinnamate salts of Salmeterol, method for production and use thereof as medicaments.
Claims (8)
1) Compounds of general formula 1 wherein R1 and R2 which may be identical or different denote hydrogen, C1-C4-alkyl, C1-C4-alkoxy, halogen, -CF3 or phenyl or if R1 and R2 are adjacent, together they represent a -CH=CH-CH=CH- bridge;
R3 denotes hydrogen, C1-C4-alkyl, C1-C4-alkoxy, halogen or -CF3, represent, optionally in the form of the enantiomers thereof, mixtures of the enantiomers or racemates thereof.
R3 denotes hydrogen, C1-C4-alkyl, C1-C4-alkoxy, halogen or -CF3, represent, optionally in the form of the enantiomers thereof, mixtures of the enantiomers or racemates thereof.
2) Compounds of general formula 1 according to claim 1, wherein R1 and R2 which may be identical or different denote hydrogen, methyl, ethyl, propyl, butyl, methoxy, fluorine, chlorine, bromine, -CF3 or phenyl, or if R1 and R2 are adjacent, together they represent a -CH=CH-CH=CH- bridge;
R3 denotes hydrogen, methyl, ethyl, methoxy, fluorine, chlorine, bromine or -CF3, optionally in the form of the enantiomers thereof, mixtures of the enantiomers or racemates thereof.
R3 denotes hydrogen, methyl, ethyl, methoxy, fluorine, chlorine, bromine or -CF3, optionally in the form of the enantiomers thereof, mixtures of the enantiomers or racemates thereof.
3) Compounds of general formula 1 according to claim 1 or 2, wherein R1 and R2 which may be identical or different denote hydrogen, fluorine, chlorine, -CF3 or phenyl R3 denotes hydrogen or fluorine, optionally in the form of the enantiomers thereof, mixtures of the enantiomers or racemates thereof.
4) Compounds of general formula 1 according to one of claims 1 to 3, wherein R1 denotes hydrogen;
R2 denotes -CF3 or phenyl;
R3 denotes hydrogen, optionally in the form of the enantiomers thereof, mixtures of the enantiomers or racemates thereof.
R2 denotes -CF3 or phenyl;
R3 denotes hydrogen, optionally in the form of the enantiomers thereof, mixtures of the enantiomers or racemates thereof.
5) Compounds of general formula 1 according to one of claims 1 to 3, wherein R1 and R2 denote chlorine;
R3 denotes hydrogen, optionally in the form of the enantiomers thereof, mixtures of the enantiomers or racemates thereof.
R3 denotes hydrogen, optionally in the form of the enantiomers thereof, mixtures of the enantiomers or racemates thereof.
6) Pharmaceutical compositions, characterised in that they contain a compound of formula 1 according to one of claims 1 to 5.
7) Use of a compound of formula 1 according to one of claims 1 to 5 for preparing a pharmaceutical composition with a betamimetic activity.
8) Use of a compound of formula 1 according to one of claims 1 to 5 for preparing a pharmaceutical composition for the treatment of asthma or COPD.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10209243.5 | 2002-03-04 | ||
| DE2002109243 DE10209243A1 (en) | 2002-03-04 | 2002-03-04 | Synergistic, well tolerated medicament combination of tiotropium salt and sparingly water-soluble salmeterol salt, useful for treating asthma or chronic obstructive pulmonary disease |
| DE10216124.0 | 2002-04-12 | ||
| DE2002116124 DE10216124A1 (en) | 2002-04-12 | 2002-04-12 | New cinnamic acid salts of salmeterol useful for the treatment of e.g. chronic obstructive pulmonary disease |
| PCT/EP2003/001644 WO2003074469A1 (en) | 2002-03-04 | 2003-02-19 | Novel cinnamate salts, method for production and use thereof as medicaments |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2477714A1 true CA2477714A1 (en) | 2003-09-12 |
| CA2477714C CA2477714C (en) | 2011-01-25 |
Family
ID=27789722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2477714A Expired - Fee Related CA2477714C (en) | 2002-03-04 | 2003-02-19 | New cinnamic acid salts, processes for the preparation thereof and use thereof as medicament |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1483231A1 (en) |
| JP (1) | JP2005519110A (en) |
| AR (1) | AR038622A1 (en) |
| AU (1) | AU2003221482A1 (en) |
| CA (1) | CA2477714C (en) |
| PE (1) | PE20030933A1 (en) |
| TW (1) | TW200404759A (en) |
| UY (1) | UY27686A1 (en) |
| WO (1) | WO2003074469A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2265276B1 (en) * | 2005-05-20 | 2008-02-01 | Laboratorios Almirall S.A. | DERIVATIVES OF 4- (2-AMINO-1-HYDROXYETHYL) Phenol as agonists of the BETA2 ADRENERGIC RECEIVER. |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZW6584A1 (en) * | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
| GB8310477D0 (en) * | 1983-04-18 | 1983-05-25 | Glaxo Group Ltd | Chemical compounds |
| US4791108A (en) * | 1987-04-13 | 1988-12-13 | Syntex (U.S.A.) Inc. | Sulfonyl-decahydro-8H-isoquino[2,1-G][1,6]-naphthyridines and related compounds useful as α2 -blockers |
| IL95590A (en) * | 1989-09-08 | 1996-06-18 | Glaxo Group Ltd | Pharmaceutical compositions comprising salmeterol and fluticasone propionate |
| RU2081108C1 (en) * | 1991-10-16 | 1997-06-10 | Циба-Гейги АГ | Additive salts of acids with the base and pharmaceutical composition showing antitumor activity |
-
2003
- 2003-02-19 JP JP2003572941A patent/JP2005519110A/en active Pending
- 2003-02-19 WO PCT/EP2003/001644 patent/WO2003074469A1/en active Application Filing
- 2003-02-19 CA CA2477714A patent/CA2477714C/en not_active Expired - Fee Related
- 2003-02-19 AU AU2003221482A patent/AU2003221482A1/en not_active Abandoned
- 2003-02-19 EP EP03717188A patent/EP1483231A1/en not_active Withdrawn
- 2003-02-27 UY UY27686A patent/UY27686A1/en not_active Application Discontinuation
- 2003-02-28 PE PE2003000197A patent/PE20030933A1/en not_active Application Discontinuation
- 2003-02-28 AR ARP030100660A patent/AR038622A1/en not_active Application Discontinuation
- 2003-03-03 TW TW092104401A patent/TW200404759A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003074469A1 (en) | 2003-09-12 |
| AR038622A1 (en) | 2005-01-19 |
| TW200404759A (en) | 2004-04-01 |
| CA2477714C (en) | 2011-01-25 |
| PE20030933A1 (en) | 2003-12-15 |
| JP2005519110A (en) | 2005-06-30 |
| UY27686A1 (en) | 2003-10-31 |
| EP1483231A1 (en) | 2004-12-08 |
| AU2003221482A1 (en) | 2003-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY136034A (en) | New medicaments for the treatment of chronic obstructive pulmonary disease | |
| CA2562859A1 (en) | Novel enantiomerically pure beta-agonists, method for the production and the use thereof in the form of a drug | |
| JP2002513793A5 (en) | ||
| CA2646962A1 (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
| UA81635C2 (en) | 2,5-dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12. | |
| JP2007532627A5 (en) | ||
| WO2006018222A8 (en) | Hydrates and polymorphs of 4-[[(7r)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-4-6-oxo-2-piperidinyl]amino]-3-methoxy-n-(1-methyl-4-piperidinyl) benzamide, methods for the production thereof, and use thereof as medicaments | |
| TW200616995A (en) | Novel compounds | |
| JP2006525267A5 (en) | ||
| JP2010503688A5 (en) | ||
| JP2007522111A5 (en) | ||
| TW200503674A (en) | Therapeutic agents | |
| NZ515282A (en) | Substituted phenyl compounds with immunosuppressing activity and pharmaceutical compositions | |
| MY130316A (en) | Quaternary ammonium compounds | |
| JP2005511698A5 (en) | ||
| JO2937B1 (en) | Peptidic Vasopressin Receptor Agonists | |
| IL183636A0 (en) | Quinoline derivative, use and production thereof, and drug containing the same | |
| IL183373A0 (en) | 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof | |
| EP2269694A3 (en) | Antituberculous composition comprising oxazole compounds | |
| CA2576067A1 (en) | Diarylmethyl piperazine derivatives, preparations thereof and uses thereof | |
| MY139454A (en) | 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists | |
| JP2005529965A5 (en) | ||
| CA2477714A1 (en) | New cinnamic acid salts, processes for the preparation thereof and use thereof as medicament | |
| CA2587891A1 (en) | 1-[(6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)alylpiperazine derivatives | |
| CA2547243A1 (en) | N-aryl piperidine substituted biphenylcarboxamides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20140219 |